Price M R, Pimm M V, Baldwin R W
Br J Cancer. 1982 Oct;46(4):601-10. doi: 10.1038/bjc.1982.244.
Two mouse monoclonal antibodies against the human osteogenic sarcoma 791T were examined for their capacity to exert complement-dependent cytotoxicity against a panel of human tumour cell lines. Cytotoxicity was most evident against the immunizing tumour 791T although significant reactivity was directed against other osteogenic sarcomas. In admixture, the 2 antibodies displayed synergism in their cytotoxicity although this was only demonstrable with defined ranges of antibody concentration. The cytotoxicity of these antibodies was dependent upon the use of rabbit serum as complement and no tumour-cell lysis was produced using human, guinea-pig or mouse serum complement. The more potent cytotoxic antibody failed to modify the outgrowth of 791T tumour xenografts in immunodeprived mice even though localization of antibody at the tumour site has been demonstrated (Pimm et al., 1982).
检测了两种针对人成骨肉瘤791T的小鼠单克隆抗体对一组人肿瘤细胞系发挥补体依赖性细胞毒性的能力。细胞毒性对免疫原性肿瘤791T最为明显,尽管对其他成骨肉瘤也有显著反应。混合使用时,这两种抗体在细胞毒性方面表现出协同作用,不过这仅在特定的抗体浓度范围内可得到证明。这些抗体的细胞毒性依赖于使用兔血清作为补体,而使用人、豚鼠或小鼠血清补体则不会产生肿瘤细胞裂解。尽管已经证明更有效的细胞毒性抗体在免疫缺陷小鼠中能定位于肿瘤部位,但它未能改变791T肿瘤异种移植物的生长(Pimm等人,1982年)。